Preliminary efficacy and tolerability profiles of first versus second-generation Long-Acting Injectable Antipsychotics in schizophrenia: A systematic review and meta-analysis
| Autor: | Juan Manuel Millán Alanís, Karen Iscely García Cervantes, Mauricio Méndez Hernández, Farid Carranza Navarro, Jorge Alberto Zúñiga Hernández, Víctor Daniel Acuña Rocha, Stefan Mauricio Fernández Zambrano, Neri Alejandro Álvarez Villalobos, Andrea Fernanda Guerrero Medrano, Erasmo Saucedo Uribe, César Marcelo Hinojosa Cavada |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Fluphenazine
medicine.medical_specialty Piperazines law.invention 03 medical and health sciences Benzodiazepines 0302 clinical medicine Randomized controlled trial law Internal medicine medicine Humans Paliperidone Biological Psychiatry Risperidone Positive and Negative Syndrome Scale business.industry 030227 psychiatry Discontinuation Psychiatry and Mental health Tolerability Olanzapine Meta-analysis Schizophrenia business 030217 neurology & neurosurgery medicine.drug Antipsychotic Agents |
| Zdroj: | Journal of psychiatric research. 129 |
| ISSN: | 1879-1379 |
| Popis: | We performed a systematic review and meta-analysis of the efficacy and safety of second generation (SG) long-acting antipsychotics (LAIAs) versus first generation (FG) LAIAs in schizophrenia. We conducted a comprehensive search in PubMed, MEDLINE, EMBASE and PsycINFO until May 2019. Inclusion criteria for randomized trials included: (1) patients ≥18 years with schizophrenia, (2) efficacy evaluated through the Positive and Negative Syndrome Scale (PANSS), (3) safety assessment through clinimetry, laboratory analysis, somatometry or adverse events, and (4) treatment duration ≥12 weeks. Data was synthesized using mean differences (MD) for continuous outcomes and risk ratios (RR) for dichotomous outcomes using a random-effect model. Of 1872 citations, 17 trials were included, and direct comparisons of SG vs FG-LAIAs were observed in 3 (n = 459). SG and FG-LAIAs had similar effects on PANSS scores (MD -1.35; 95% CI -8.33-5.64), tardive dyskinesia (RR 0.99; 95% CI, 0.47–2.07), all-cause discontinuation (RR 1.01; 95% CI 0.75–1.36), discontinuation due to inadequate efficacy (RR 1.13; 95% CI 0.81–1.59) or adverse events (RR 1.08; 95% CI 0.55–2.11). SG-LAIAs reduced the risk of using antiparkinsonian drugs (RR 0.54; 95% CI 0.54–0.76) but significantly increased serum prolactin, weight and BMI. For long-term management, depot preparations of paliperidone, haloperidol, risperidone and fluphenazine were equally effective at symptom control and adherence, with significant differences in their safety profiles. These results however are considerably limited due to the small number of included studies and are therefore preliminary, not generalizable. More clinical trials are required to obtain a broader perspective of SG-LAIAs compared to FG-LAIAs. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect